| Apellido | SANTORO |
| Nombre | ARMANDO |
| ID | 6816347 |
"Su solicitud se enviará en seg. Por favor espere."
SUGERENCIAS
Santoro, A. Autor ID: 5521680 ver autor
Articulos ( 3 en total )
● Aurocyanide adsorption onto granular activated carbon impregnated with SDS anionic surfactant, 2022
● Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: An international, multicenter, comparative cohort study, 2021
● The distribution of sediment residence times at the foot of mountains and its implications for proxies recorded in sedimentary basins, 2020
Afiliaciones ( 3 en total )
● Pontificia Universidad Católica de Chile
● Universidad de Antofagasta
● Universidad de Concepción
ÁREA DE TRABAJO
FIRMA SELECCIONADA COMO BASE
Santoro, Armando Autor ID: 6816347 ver autor
Articulos ( 5 en total, se muestran 3 )
● Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW., 2024
● Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma, 2024
● Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study, 2023
Afiliaciones ( 3 en total )
● Humanitas Univ
● IRCCS Humanitas Res Hosp
● IRCCS Humanitas Res Hospital Humanitas Canc Ctr R
FIRMAS SELECCIONADAS PARA AGRUPAR